Research Project

Name of FacultyResearch Project
Dr. Arvind KankaneRole of Trenexamic Acid in Intra cerebaral Hemorrhage
Efecctiveness of RTMS in Fibromyelgia ; A redomize Cntrol trial
Prof. Dr. Nutan Kumar Agrawal
Dr. Mohd. Zaki Siddiqui
A post-marketing study, Randomized, Multicentric Clinical Study to Assess the Safety andEfficacy of an IVsecurement dressing, VELFIX EDGE + CHG in comparison to Tegaderm™ CHG in Reducing CatheterRelated Bloodstream Infections (CRBSIs)
Protocol No: DMPL/CIP-008
2025/CT/VF
Prof. Dr. Nutan Kumar AgrawalA Multicenter, Randomized,Comparative, Active Controlled,Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety and Immunogenicityof Semaglutide Injection in WeightManagement
Protocol No: (ICR/23/013)
Prof. Dr. Nutan Kumar Agrawal
Dr. Mohd. Zaki Siddiqui
A Phase IV, Prospective, Multi-centre, Open label, Randomized Two-Arm Study to Assess the Safety,Tolerability and Efficacy of Inosine
Pranobex 500 and 1000 mg Tablets
Manufactured by Themis Medicare Ltd in Patients with Influenza andOther Acute Respiratory ViralInfections
TML/IAD/05 V 01; 06 October 2023.
Prof. Dr. Nutan Kumar Agrawal
Dr. Mohd. Zaki Siddiqui
Prospective, Randomized,Comparative, Parallel Group, Study to Evaluate the Safety and Efficacy of ORS of Mystical Biotech Pvt Ltd versus Traditional Marketed ORS in
Subjects with Diarrhea
Protocol ID- ORS/MYS/OBS/2024
Prof. Dr. Nutan Kumar Agrawal
Dr. Mohd. Zaki Siddiqui
A Phase III, MultiCenter,Randomized, Double Blind, Active-controlled, Parallel group study to
evaluate the Efficacy and Safety of Vonoprazan 20mg tablets compared toPantoprazole 40mg tablets in Patients with GastroesophagealReflux Disease (GERD)
Protocol No:
HCR/III/VONONERD/12/2022
Dr. Mohd. Zaki SiddiquiA prospective, randomized, parallel, three-arm, open-label, multicenter, phase IV clinical trial to evaluate the immunological non-interference of Typhoid Vi conjugate vaccine with Yellow fever vaccine administered to healthy subjects.
Project No. 23-01
(Version No. 02; Dated 14/08/2023)
Dr. Mohd. Zaki SiddiquiA Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicentric, Phase II Clinical Study to Evaluate Safety and Efficacy of Azelastine 0.1% Nasal Spray in Non-hospitalized Patients with Mild COVID-19 Infection.
Protocol No.: URSA-CARVIN-II-001
Dr. Mohd. Zaki SiddiquiA Prospective, Randomized, Multi-Center, Open-label, Interventional Study to Evaluate theSafety and Efficacy of Imusil® (KutkiExtract 200 mg + Guduchi extract 60 mg + Amla extract 60 mg) tablet in Treatment of Adult Subjects with mildCOVID-19
Protocol No. - IMU/GLPL/PHASE IV/2022 Version:1.0 dated 02 Feb 2022
Prof. Dr. Nutan Kumar AgrawalA Multicenter, Randomized,Comparative, ActiveControlled, Open-Label, Phase 3Study toEvaluate the Efficacy and Safety of
Semaglutide Injection in Comparison
with Reference Biologic in Type 2Diabetes Mellitus.
Protocol No: ICR/23/010
Prof. Dr. Nutan Kumar Agrawal
Dr. Mohd. ZakiSiddiqui
A Phase IV, Postmarketing,Prospective, Multicentric, Single Arm Study to Evaluate the SafetyandEfficacy of Vonoprazan 20mg in Adult Patients with Approved Indications.
HCR/IV/VONONERD/08/2024
Dr. Mohd. ZakiSiddiquiA prospective, multi-centric, open-labeled, phase-IV study to assesssafety and efficacy of LYFAQUIN™
(Centhaquine Citrate) as aresuscitative agent for hypovolemic shock to be usedas an adjuvant to standard treatment of shock.
Protocol No.: PMZ-2010/CT
4.1/2019; Version No.: 1.0;
Dr. Om Shankar Chourasia M.D (Paediatrics)Study Title: A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease.
Study Code: D4800L00014
Dr.SuvashSahu
Dept. of Dermatology
A Prospective, Multicenter, Parallel Group, Randomized, Assessor Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ruxolitinib 1.5% Cream in comparison to Pimecrolimus 1% Cream for the treatment of patients with Mild to Moderate Atopic Dermatitis (AD)
ICR/25/007
Dr. Vidya Chaudhary Dept. of Obs. &GynaeA Prospective, Multi-Centric, Single-Arm, Open-label, Phase IV Study to Assess the Safety and Efficacy of Elagolix for Treatment of Moderate to Severe Pain Associated with Endometriosis.ICR/24/012
Dr.Madhurmay
M.D(T.B and Respiratory Diseases)
A Prospective, Randomized, Multi-Centric, Two-Arm, Active-Controlled, Parallel- Group, Assessor-blind, Phase III, Comparative Study to Evaluate Efficacy and Safety of Fixed Dose Combinationof Umeclidinium/Vilanterol Compared to Fixed Dose Combination of Indacaterol/Glycopyrronium in Patienmicro
ts with Chronic Obstructive Pulmonary Disease
ICR/25/020
Dr.Arvind Kumar Kankane
M.D (Medicine) D.M(Neurology)
Study Title: “A Prospective, Multicenter, Randomized, Assessor blind, Parallel-group, Active-Controlled, Phase III Comparative Study to Evaluate the Efficacy and Safety of Suvorexant Tablets in Comparison to Lemborexant Tablets in Patients with Insomnia. (ICR/25/017)”
Dr.Arvind Kumar Kankane
M.D (Medicine) D.M(Neurology)
Study Title: “A Prospective, Multicenter, Single arm, Open-label, Phase IV Study to Assess the Safety and Efficacy of Gabapentin Extended Release Tablets in Patients with Postherpetic Neuralgia and Other Neuropathic Pain.” (ICR/23/003)
Dr.Madhurmay
M.D(T.B and Respiratory Diseases)
Study Title: “A Randomized, Multi-Centric, Two-Arm, Active-Controlled, Parallel-Group, Open-Label, Phase III, Comparative Study to Evaluate Efficacy and Safety of Revefenacininhalation solution Compared to Tiotropium Bromide Powder for Inhalation in Patients with Chronic Obstructive Pulmonary Disease” ICR/25/004
Dr.SuvashSahu
Dept. of Dermatology
Title: “A Randomized, Multi-Centric, Two-Arm, Active-Controlled, Parallel-group, Assessor-Blind, Phase III, Comparative Study to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream Compared to Calcipotriol 0.005% Ointment in Patients with Chronic Plaque Psoriasis.”ICR/25/003
Dr. Nutan Kumar Agrawal
M.D(Medicine)
Study Title:A post-marketing study, Randomized, Multicentric Clinical Study to Assess the Safety and Efficacy of an IV securement dressing, VELFIX EDGE + CHG in comparison to Tegaderm™ CHG in Reducing Catheter-Related Bloodstream Infections (CRBSIs)
Version No. & Date: 1.0; 10-Oct-2025
Dr.Madhurmay
M.D(T.B and Respiratory Diseases)
Protocol Title :-“A Randomized, Multi-Centric, Two-Arm, Active-Controlled, Parallel-Group, Open-Label, Phase III, Comparative Study to Evaluate Efficacy and Safety of Fixed Dose Combination of Fluticasone Furoate, Umeclidinium and Vilanterol Compared to Fixed Dose Combination of Indacaterol, Glycopyrronium and MometasoneFuroate in Patients with Bronchial Asthma (ICR/24/015)”
Protocol No: ICR/24/015
Dr.Jitendra Kumar
M.S (Opthalmology)
Protocol Title :-“A Prospective, Multicenter, Double-Blind, Active-Controlled, Parallel-Group, Phase III Study to Compare the Efficacy, Safety and Immunogenicity of Sun’s Aflibercept with Reference Biologic in Patients with Neovascular Age-Related Macular degeneration (WET AMD)”
Protocol No: ICR/24/006
Dr.Arvind Kumar Kankane
M.D (Medicine) D.M(Neurology)
Protocol Title:A Prospective, Multi-Center, Double blind, Comparative, Active-Controlled, Parallel Group, Randomized Study to Evaluate the Efficacy and Safety of Fixed Dose Combination (FDC) of Pregabalin ER 82.5mg and Polmacoxib 2mg compared to Pregabalin 75 mg and Etoricoxib 60mg in Indian Adult Patients with Chronic Lower Back Pain.
HCR/III/POLPRELBP/02/2023
Dr. Rajat.V.KMisurya
M.D.S ( Oral & Maxillofacial )
Protocol Title: “Evaluation of Efficacy and Safety of Aceclofenac + Paracetamol + Serratiopeptidase Combination After Impacted Lower Third Molar Surgery: A Randomized, Double-Blind Comparison with Aceclofenac + Paracetamol Combination”
Protocol ID- Ipca/APSP/PIV-21.
Dr.Arvind Kumar Kankane
M.D (Medicine) D.M(Neurology)
Protocol Title: A prospective, multicentric, randomized, double-blind, parallel, phase IV study to assess the safety and efficacy of TycamzziTM (sovateltide) in patients with acute cerebral ischemic stroke.
StudyProtocolNo.:Sovateltide/CT-4.1/2022
Dr. Archana H Lanje
M.D.S ( Oral & Maxillofacial Pathology and Microbiology )
Protocol Title: A Prospective, Multicentric, Double blind, Randomized, Active Controlled, Parallel Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Polmacoxib 2mg and Paracetamol 325mg compared to Fixed Dose Combination of Etoricoxib 60mg and Paracetamol 325mg in Adults with Acute Pain due to Dental Extraction.
Protocol- HCR/III/POLPARAPI/03/2023
Dr. Anshul Jain
MD (Anaesthesiology)
Study Protocol No.: PMZ-2010/CT-4.1/2019; Version No.: 1.0; Date: 16-Oct-2019
Reference: A prospective, multi-centric, open-labeled, phase-IV study to assess safety and efficacy of LYFAQUIN™ (Centhaquine Citrate) as a resuscitative agent for hypovolemic shock to be used as an adjuvant to standard treatment of shock.
DR. SuvashSahu
M.D (Dermatology)
Protocol Title:“ A Phase III, Multi-Center, Double Blind, Comparative, Randomised, Prospective, Parallel Study to evaluate the Efficacy and Safety Naftifine Hydrochloride Gel 2% in patients with InterdigitalTineaPedis”
Protocol No: HCR/III/NAFITP/10/2019
Dr. Anshul Jain
MD (Anaesthesiology)
Protocol Title:“A Randomized, Single Blind, Placebo Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Ursodiol Injection 625mg/25ml (25mg/ml) in Adults with moderate COVID 19 patients at a dose of 1750 mg/day via intravenous infusion”
URSO/SML/P2/2021, V 2.0 dated 14 Sep 2021
Dr.Arvind Kumar Kankane
M.D (Medicine) D.M(Neurology)
A Phase III, Multi-centric, Prospective, Randomized, Parallel study to Evaluate the Efficacy and Safety of Molnupiravir Capsule in Adult Indian Patients with Mild COVID-19
HCR/III/MOLCOV/04/2021-01
Version 3.0 dated 07 MAY 2021
Dr.Arvind Kumar Kankane
M.D (Medicine) D.M(Neurology)
A Phase III, Multi-centric, Prospective, Randomized, Parallel study to Evaluate the Efficacy and Safety of Molnupiravir Capsule in Adult Indian Patients with Moderate COVID-19
HCR/III/MOLCOV/04/2021-01
Version 3.0 dated 07 MAY 2021

MAHARANI LAXMIBAI MEDIAL COLLEGE JHANSI

Contact No

0510-2321446

Email ID:

: info@mlbmcj.in

LOGOK
MLBMC JHANSI
Maharani Laxmibai Medial College, Jhansi
महारानी लक्ष्मीबाई मेडिकल कॉलेज, झांसी
Approved by NMC (National Medical Comission) and five UG Programs accredited by NBA
Affiliated to Atal Bihari Vajpayee Medical University, Lucknow
MAHARANI LAXMIBAI MEDIAL COLLEGE JHANSI
Copyright©2025, Maharani Laxmibai Medial College, Jhansi.
All Rights Reserved.

Visitors: 57750
Scroll to Top
Scroll to Top